Journal of Alzheimers Disease, 39 (2): 315-329
INTRODUCTION

24
Statins are HMG-CoA reductase inhibitors used to 25 treat hypercholesterolemia, and it is known that some 
BSA-TBS-T). Membranes were thoroughly washed
300
Statistical analysis was performed using ANOVA. All 301 results are presented as mean ± SEM.
302
RESULTS
303
LTP measurements in AβPPswe/PS1dE9 mice
304
The magnitude of LTP in the CA1 region measured (153.6 ± 13.6%, n = 9) and their age-matched controls 312 (158.2 ± 13.6%, n = 9, p ≥ 0.05) (Fig. 1A) .
313
The magnitude of LTP was significantly reduced 314 in hippocampal slices from 8 month old A␤PPswe/ 315 PS1dE9 mice (124.0 ± 7.7%, n = 6) compared to con-316 trols (182.7 ± 16.4%, n = 9, p ≤ 0.05) (Fig. 1B) . This (n = 9), was similar to age-matched wild type (Wt) littermates (n = 9). B) LTP was impaired in A␤PPswe/PS1dE9 hippocampal slices at 8 months (n = 6) compared to age-matched Wt littermates (n = 9, p < 0.05). C) Slices from 18 month old A␤PPswe/PS1dE9 (n = 6) had a deficit in LTP compared to Wt littermates (n = 10, p < 0.05). D) Bar charts summarizing LTP in Wt and A␤PPswe/PS1dE9 mice at 6, 8, and 18 months.
brain content of A␤, we examined levels of water- 18 months (815.3 ± 121.7, n = 6, p ≤ 0.05) (Fig. 2E) .
377
These results demonstrate that the vast majority of A␤ 378 at the three time points studied is present in water-and 379 detergent-insoluble deposits and that the levels of TBS- (182.7 ± 16.4%, n = 9, p ≥ 0.05) (Fig. 3A) . However, and TBS-TX-soluble A␤, but due to the inherent vari- Fig. 3 . Chronic SV treatment rescued LTP deficits in slices from 8 month old A␤PPswe/PS1dE9 mice. A) Chronic SV had no significant effect on LTP recorded in slices from 8 month old wild type (Wt) mice (199.4 ± 16.9%, n = 8, p = 0.49) compared to age matched non-treated wild types (182.7 ± 16.4%, n = 9). B) LTP deficits observed in slices from 8 month A␤PPswe/PS1dE9 mice were significantly reduced following one month SV treatment (191.5 ± 12.1%, n = 7) compared to untreated A␤PPswe/PS1dE9 (124.0 ± 7.7%, n = 6, p ≤ 0.001). The magnitude of LTP was similar to age matched control levels in the treated and non-treated conditions in both cases (p > 0.05). The black arrow represents time of HFS. Above each set of graphs, representative fEPSPs are shown that were recorded at the times indicated by the numbers on each graph. All values are presented as the mean ± SEM of the fEPSP slope normalized from the baseline. Statistical analysis was performed using an unpaired Students t-test. ability in the levels of A␤ in different animals, this 416 reduction was not statistically significant. SV treat-417 ment also had no effect on the levels of the FA-soluble 418 A␤ species (413.4 ± 37.0, n = 6) which was similar 419 to the level in the age-matched non treated group 420 (384.1 ± 78.8, n = 6, p ≥ 0.05). A␤ levels in the FA 421 fraction are expressed in ng/g wet brain (Fig 4D) . (Fig. 5C) . 
The level of p-GSK3 was significantly lower in
458
A␤PPswe/PS1dE9 mice (82.8 ± 2.2%, n = 6) com-459 pared to age-matched wild types (100.0 ± 6.7%, n = 6) 460 (Fig. 6A ), but this was overcome by SV treatment that 461 caused a significant increase in the level of p-GSK3 in 462 SV-treated A␤PPswe/PS1dE9 mice (119.9 ± 11.7%, 463 n = 4, p = 0.005). However, SV had no effect on 464 p-GSK3 levels in wild type mice (104.1 ± 4.9%, n = 5, 465 p ≥ 0.05) (Fig. 6A) . In contrast the level of total GSK3 466 was similar in all four groups; wild type (100.0 ± 5.3% 467 (n = 6); A␤PPswe/PS1dE9 (92.58 ± 2.1%, n = 6); SV- (Fig. 6B) . The phospho-GSK3/total GSK3 animals (see Supplementary Fig. 2 ). A) The level of p-Akt was similar in wild type (100.0 ± 3.5%, n = 6) and A␤PPswe/PS1dE9 mice (91.8 ± 5.9%, n = 6). SV treatment had no significant effect on the p-Akt levels in wildtype compared to non-treated mice (110.5 ± 7.8%, n = 5, p = 0.22). P-Akt levels were increased significantly in SV-treated A␤PPswe/PS1dE9 mice compared to the non-treated group (112.1 ± 4.0%, n = 4, p = 0.03). B) There was no change in the level of total Akt across the control, transgenic and SV-treated groups. C) The p-Akt/total Akt ratio in SV-treated wild type mice (1.196 ± 0.132, n = 5) was similar to non-treated mice (1.003 ± 0.043, n = 6. p = 0.17). SV-treated A␤PPswe/PS1dE9 mice had a significantly higher p-Akt/total Akt ratio (1.158 ± 0.057, n = 4) compared to the non-treated transgenic group (0.960 ± 0.057; n = 6, p ≤ 0.05). p ≤ 0.05) compared to untreated A␤PPswe/PS1dE9 500 mice (3.04 ± 0.30 mM; n = 6) ( Supplementary Fig. 1 ).
501
DISCUSSION
502
In this study we have investigated the correlation . SV treatment restores activation of GSK3 in A␤PPswe/PS1dE9 mice. A) p-GSK3 levels were significantly lower in brain homogenates from 8 month old A␤PPswe/PS1dE9 mice (82.8 ± 2.2%, n = 6) compared to age matched wild types (100.0 ± 6.7%, n = 6, p ≤ 0.05). SV treatment had no significant effect on the p-GSK3 levels in wild type mice (104.1 ± 4.9%, n = 5) compared to untreated wild type mice. The level of p-GSK3 in SV-treated A␤PPswe/PS1dE9 mice was significantly increased (119.9 ± 11.7%, n = 4, p ≤ 0.005). B) Levels of total GSK3 were similar in all groups. C) The p-GSK3/totalGSK3 ratio was significantly lower in A␤PPswe/PS1dE9 mice (0.897 ± 0.035, n = 6) compared to agematched wild types (0.997 ± 0.016, n = 6, p ≤ 0.05). The p-GSK3/total GSK3 ratio was significantly increased in SV-treated A␤PPswe/PS1dE9 mice (1.176 ± 0.059, n = 4; p ≤ 0.005) and SV treated wild types (1.166 ± 0.043, n = 5; p ≤ 0.005) compared to untreated mice. The ratio of p-GSK3/total GSK3 was similar between SV-treated A␤PPswe/PS1dE9 and SV-treated wild types. excitability of neurons in AD mouse models [52, 53] .
537
In our study, we focused on synaptic plasticity in the 
579
In our study, we quantified A␤ levels in the soluble, 
Effects of chronic SV treatment
614
The dose of SV used in our study is high compared to (Fig. 3A) . However, the LTP impairments observed in 662 slices at 8 months from A␤PPswe/PS1dE9 mice were 663 reversed following SV treatment (Fig. 3B) 
694
We therefore investigated the levels of activated (phos- 
